scholarly journals High-frequency (20-50 MHz) ultrasonography of pseudoxanthoma elasticum skin lesions

2013 ◽  
Vol 169 (6) ◽  
pp. 1233-1239 ◽  
Author(s):  
M. Guérin-Moreau ◽  
G. Leftheriotis ◽  
Y. Le Corre ◽  
M. Etienne ◽  
R. Amode ◽  
...  
Keyword(s):  
High Frequency ◽  
Pseudoxanthoma Elasticum ◽  
Skin Lesions

scholarly journals Morphologic Features of Cutaneous T-Cell Lymphomas Using Dermoscopy and High Frequency Ultrasound

2020 ◽  
Vol 10 (1) ◽  
pp. 17
Author(s):  
Iris Wohlmuth-Wieser ◽  
Joel M. Ramjist ◽  
Neil Shear ◽  
Raed Alhusayen
Keyword(s):  
T Cell ◽  
High Frequency ◽  
Early Stage ◽  
Skin Lesions ◽  
Diagnostic Tools ◽  
Skin Thickness ◽  
High Frequency Ultrasound ◽  
T Cell Lymphomas ◽  
Standardized Parameters ◽  
Frequency Ultrasound

The diagnosis of cutaneous T-cell lymphomas (CTCL) is frequently delayed by a median of three years and requires the clinical evaluation of an experienced dermatologist and a confirmatory skin biopsy. Dermoscopy and high-frequency ultrasound (HFUS) represent two non-invasive diagnostic tools. While dermoscopy is inexpensive and widely used for the diagnosis of melanoma and non-melanoma skin cancers, HFUS of skin lymphomas represents a novel diagnostic approach that is not yet implemented in the routine dermatologic practice. The aim of our study was to prospectively assess skin lesions of patients with either CTCL patches or plaques with dermoscopy and HFUS and to compare the findings with atopic dermatitis (AD) and psoriasis. Thirteen patients with an established diagnosis of CTCL, psoriasis, or AD were studied: Dermoscopy features including spermatozoa-like structures and the presence of white scales could assist in differentiating between early-stage CTCL and AD. HFUS measurements of the skin thickness indicated increased epidermal-, thickness in CTCL, and psoriasis compared with AD. Our results support the use of dermoscopy as a useful tool to diagnose CTCL. HFUS could augment the dermatologic assessment, but further studies will be needed to define standardized parameters.

Pseudoxanthoma elasticum-like skin lesions with congenital erythropoietic porphyria

2014 ◽  
Vol 24 (3) ◽  
pp. 401-402 ◽  
Author(s):  
Yoshiko Mine ◽  
Akira Iwanaga ◽  
Susumu Ikehara ◽  
Yuta Koike ◽  
Noboru Takamura ◽  
...  
Keyword(s):  
Pseudoxanthoma Elasticum ◽  
Skin Lesions ◽  
Congenital Erythropoietic Porphyria

Dermoscopic phenotype of pseudoxanthoma elasticum skin lesions: a study of 16 patients

2019 ◽  
Vol 33 (7) ◽  
Author(s):  
C. Berthin ◽  
A. Phan ◽  
N. Navasiolava ◽  
S. Michalak ◽  
H. Humeau ◽  
...  
Keyword(s):  
Pseudoxanthoma Elasticum ◽  
Skin Lesions

Pseudoxanthoma elasticum-like skin lesions and angioid streaks in β-thalassemia

1992 ◽  
Vol 41 (3) ◽  
pp. 159-164 ◽  
Author(s):  
Athanasios Aessopos ◽  
Panayotis Savvides ◽  
George Stamatelos ◽  
Thomas Tassiopoulos ◽  
Phaedon Kaklamanis ◽  
...  
Keyword(s):  
Pseudoxanthoma Elasticum ◽  
Skin Lesions ◽  
Angioid Streaks

High-frequency sonography and color Doppler in the management of pigmented skin lesions

2003 ◽  
Vol 29 (6) ◽  
pp. 875-879 ◽  
Author(s):  
Bertrand Bessoud ◽  
Nathalie Lassau ◽  
Serge Koscielny ◽  
Christine Longvert ◽  
Marie-Francoise Avril ◽  
...  
Keyword(s):  
High Frequency ◽  
Color Doppler ◽  
Skin Lesions ◽  
Pigmented Skin Lesions

scholarly journals Therapy of Pseudoxanthoma Elasticum: Current Knowledge and Future Perspectives

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1895
Author(s):  
Max Jonathan Stumpf ◽  
Nadjib Schahab ◽  
Georg Nickenig ◽  
Dirk Skowasch ◽  
Christian Alexander Schaefer
Keyword(s):  
Current Knowledge ◽  
Treatment Options ◽  
Pseudoxanthoma Elasticum ◽  
Skin Lesions ◽  
Arterial Calcification ◽  
Future Perspectives ◽  
Strong Inhibitor ◽  
New Therapeutic Approaches ◽  
Pathogenic Variants ◽  
Abcc6 Gene

Pseudoxanthoma elasticum (PXE) is a rare, genetic, metabolic disease with an estimated prevalence of between 1 per 25,000 and 56,000. Its main hallmarks are characteristic skin lesions, development of choroidal neovascularization, and early-onset arterial calcification accompanied by a severe reduction in quality-of-life. Underlying the pathology are recessively transmitted pathogenic variants of the ABCC6 gene, which results in a deficiency of ABCC6 protein. This results in reduced levels of peripheral pyrophosphate, a strong inhibitor of peripheral calcification, but also dysregulation of blood lipids. Although various treatment options have emerged during the last 20 years, many are either already outdated or not yet ready to be applied generally. Clinical physicians often are left stranded while patients suffer from the consequences of outdated therapies, or feel unrecognized by their attending doctors who may feel uncertain about using new therapeutic approaches or not even know about them. In this review, we summarize the broad spectrum of treatment options for PXE, focusing on currently available clinical options, the latest research and development, and future perspectives.

Sign in / Sign up

Export Citation Format

Share Document